PDF(Pubmed)
Abstract：
Background: Vitamin C has been used as an antioxidant and has been proven effective in boosting immunity in different diseases, including coronavirus disease (COVID-19). An increasing awareness was directed to the role of intravenous vitamin C in COVID-19. Methods: In this study, we aimed to assess the safety of high-dose intravenous vitamin C added to the conventional regimens for patients with different stages of COVID-19. An open-label clinical trial was conducted on patients with COVID-19. One hundred four patients underwent high-dose intravenous administration of vitamin C (in addition to conventional therapy), precisely 10 g in 250 cc of saline solution in slow infusion (60 drops/min) for three consecutive days. At the same time, 42 patients took the standard-of-care therapy. Results: This study showed the safety of high-dose intravenous administration of vitamin C. No adverse reactions were found. When we evaluated the renal function indices and estimated the glomerular filtration rate (eGRF, calculated with the CKD-EPI Creatinine Equation) as the main side effect and contraindication related to chronic renal failure, no statistically significant differences between the two groups were found. High-dose vitamin C treatment was not associated with a statistically significant reduction in mortality and admission to the intensive care unit, even if the result was bound to the statistical significance. On the contrary, age was independently associated with admission to the intensive care unit and in-hospital mortality as well as noninvasive ventilation (N.I.V.) and continuous positive airway pressure (CPAP) (OR 2.17, 95% CI 1.41-3.35; OR 7.50, 95% CI 1.97-28.54; OR 8.84, 95% CI 2.62-29.88, respectively). When considering the length of hospital stay, treatment with high-dose vitamin C predicts shorter hospitalization (OR -4.95 CI -0.21--9.69). Conclusions: Our findings showed that an intravenous high dose of vitamin C is configured as a safe and promising therapy for patients with moderate to severe COVID-19.
摘要：
背景：维生素C已被用作抗氧化剂，并已被证明可有效增强不同疾病的免疫力，包括冠状病毒病（COVID-19）。人们越来越意识到静脉注射维生素C在COVID-19中的作用。方法:在本研究中,我们旨在评估不同阶段COVID-19患者在常规治疗方案中添加大剂量静脉注射维生素C的安全性.对COVID-19患者进行了一项开放标签临床试验。104例患者接受了大剂量静脉注射维生素C（除常规治疗外），在缓慢输注（60滴/分钟）的250cc盐溶液中精确地10g连续三天。同时,42名患者接受了标准治疗。结果:本研究显示大剂量静脉注射维生素C的安全性,未发现不良反应。当我们评估肾功能指标并估计肾小球滤过率时(eGRF，用CKD-EPI肌酐方程计算）作为与慢性肾功能衰竭相关的主要副作用和禁忌症，两组间差异无统计学意义。高剂量维生素C治疗与死亡率和重症监护病房入院的统计学显着降低无关。即使结果与统计学意义有关。相反,年龄与入住重症监护病房和院内死亡率以及无创通气(N.I.V.)和持续气道正压通气(CPAP)独立相关(分别为OR2.17,95%CI1.41~3.35;OR7.50,95%CI1.97~28.54;OR8.84,95%CI2.62~29.88).当考虑住院时间时，高剂量维生素C治疗可缩短住院时间(OR-4.95CI-0.21--9.69).结论：我们的研究结果表明，静脉注射高剂量维生素C被配置为中度至重度COVID-19患者的安全且有希望的治疗方法。
